Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer.
Incyte
Unlock to Claim this listing
Add / Modify Company
4.23
Overall Excellence Rating
Industry
Pharmaceuticals & BiotechnologyCategory
Pharmaceutical ManufacturingESG/Ethical Impact
The entirety of our Board of Directors oversees our ESG strategy—which includes targets and initiatives that aim to reduce our environmental impact. Board Committees are responsible for various elements of ESG; for example, our Audit Committee oversees risk management and the Compensation Committee oversees compensation-related goals and targets, as well as our progress against these targets. At the management level, each Incyte location takes responsibility for monitoring and driving down its emissions, water use and waste. Incyte supports our employees’ efforts to make a difference in their communities. Through our Community Service Program, we provide an annual day of paid time off for employees to volunteer with the charitable causes they’re passionate about. In 2022, employee participation in our Community Service Program benefited communities around the world, with 250 employees reporting more than 1,500 hours of volunteer service. To promote employee volunteering, one of our key 2023 ESG targets is for at least 15% of global employees to participate in community volunteer activities through the use of their paid employee volunteer day. Matching employees contributions to the causes that are most important to them helps foster a sense of community and amplifies our collective impact. Through the program, we match employee contributions to eligible nonprofits dollar for dollar, up to a predetermined cap. Based on employee feedback, in July of 2022 we doubled the pre-determined cap. This, coupled with increased employee participation, helps us to make an even more significant difference in our communities. Strong ethics and good governance are fundamental to our success and to building long-term value for our shareholders and a positive impact for our patients, colleagues, community and environment.
Eligible Awards
Coming Soon
Claim Your Award Badges
Do you work with Us
Awards Received
2023
Revenues
3609000000
Website Traffic
Employee Rating
4.1
Customer Rating
4.3
Company Size
100-1000
ESG Risk Rating
3




